IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group - Feuring-Buske, M. (Springer, 2000)
In: 79 (2000), S. 493-500